NM_001034853.2(RPGR):c.284G>A (p.Gly95Glu) is a missense variant that replaces glycine with glutamic acid at amino acid 95. Another missense variant in the same codon, NM_001034853.2(RPGR):c.283G>A (p.Gly95Arg; PMID: 28488341) has been classified as pathogenic for RPGR-related retinopathy by the ClinGen X-linked IRD VCEP, while no benign missense variants have been identified in this codon. Glycine-to-glutamate has a lower Grantham’s distance (98) than the glycine-to-arginine (125), so PM5_Supporting cannot be met. This variant is absent from gnomAD v4.1.0 (PM2_Supporting). This variant has been reported in at least 3 apparently unrelated probands meeting one of the PS4 requirements of some functional vision impairment in affected males by age 30 years, and/or decreased or absent electroretinogram responses (PMID: 33598457, PMID: 34287692, PMID: 36445968, PS4_Moderate). At least one proband harboring this variant exhibits a phenotype including childhood onset (1 pt), rod-specific b-wave that was reduced or undetectable (1 pt), accumulation of bone spicules (0.5 pts), and reduced visual acuity (0.5 pts), with genotyping by exome sequencing using a 77-gene panel followed by a 161-gene panel that did not identify an alternative basis for retinal disease (2 pts), which together are specific for RPGR-related retinopathy (5 points, PMID 28512305, PP4). The variant has been reported to segregate with retinal dystrophy through at least 2 affected meioses from 1 family (PP1; PMID: [33598457]). The computational predictor REVEL gives a score of 0.983, which is above the ClinGen X-linked IRD VCEP threshold of ≥0.932 and predicts a damaging effect on RPGR function (PP3_Strong). In summary, this variant is classified as likely pathogenic for RPGR-related retinopathy based on the ClinGen X-linked Inherited Retinal Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for RPGR Version 1.0.0; PM2_Supporting, PS4_Moderate, PP3_Strong, PP4, and PP1.